

**Table S1** Comparison of baseline characteristics amongst patients with ECOG performance status 0–1 (n=126) and 2–4 (n=105) at initiation of osimertinib

Characteristic	ECOG PS 0–1, n (%)	ECOG PS 2–4, n (%)	P
Age ≥75 years	38 (30.2)	35 (33.3)	0.71‡
Gender			0.99†
Male	42 (33.3)	36 (34.3)	
Female	84 (66.7)	69 (65.7)	
EGFR mutation			0.48†
del19	73 (57.9)	55 (52.4)	
L858R	53 (42.1)	50(47.6)	
PD-L1 expression			0.30†
<50%/unknown	93 (73.8)	70 (66.7)	
≥50%	33 (26.2)	35 (33.3)	
Smoking status			0.11†
Never	81 (64.3)	55 (52.4)	
Former	41 (32.5)	42 (40.0)	
Current	4 (3.2)	8 (7.6)	
CCI, median	0	0	0.90‡
Brain metastases (present)	22 (17.5)	35 (33.3)	0.008†

†, P value for Chi-squared test; ‡, P value for Kruskal-Wallis rank sum test. Charlson Comorbidity Index, CCI; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; n, number of patients; PD- L1, programmed death ligand 1.